Lymphoepithelioma

Viracta Therapeutics to Host R&D Day Highlighting Nana-val in Epstein-Barr Virus (EBV)-Associated Cancers

Retrieved on: 
Wednesday, October 4, 2023
Lymphoma, PTCL, Peripheral T-cell lymphoma, Hematopoietic stem cell transplantation, Initiation, Creatinine, DLBCL, Thomas Jefferson University, Valganciclovir, Oncology, EDT, B-cell lymphoma, Stage 2, Nasopharyngeal carcinoma, Bone marrow, CRR, 2009 Tour de France, Stage 1 to Stage 11, SDD, Dor, Patient, Division, CR, Toxic leukoencephalopathy, NPC, R, FDA, Therapy, Stomach, Engagement, ORR, EBV, Pharmaceutical industry, Fine chemical, Medical device, Medical imaging, Leiomyosarcoma, Lymphoepithelioma

SAN DIEGO, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that it plans to highlight new preliminary clinical and preclinical data from studies of nanatinostat and valganciclovir (Nana-val), its all-oral investigational therapy targeting Epstein-Barr virus (EBV)-associated cancers, during an R&D Day today, Wednesday, October 4, 2023, at 8:00 a.m. EDT.

Key Points: 
  • “The clinical responses and favorable safety profile observed in multiple relapsed or refractory EBV-positive lymphoma patient populations continue to be encouraging.
  • In addition, the R&D Day will feature presentations by expert key opinion leaders who will discuss the high unmet medical needs of EBV-associated lymphomas.
  • Enrollment completed through the fifth dose level of the Phase 1b dose escalation portion of the trial without any dose-limiting toxicities reported.
  • A live video webcast of the presentation will be available here and on the Investors section of the Viracta website under " Events and Webcasts ".

Viracta Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, August 14, 2023
Lymphoma, PTCL, Patent, Peripheral T-cell lymphoma, Extranodal NK/T-cell lymphoma, nasal type, Probability, Drug development, Hematology, Creatinine, DLBCL, Crizotinib, Valganciclovir, United States patent law, G&A, CMO, B-cell lymphoma, Stage 2, Transplant, Journal, American Society of Hematology, State, Patient, Investment, Cytopenia, EBV, Bone marrow, T-cell lymphoma, Financial toxicity, R, Research, FDA, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patent and Trademark Office, Stomach, Society, Food, Pharmaceutical industry, Vaccine, Platinum, Fine chemical, Leiomyosarcoma, Lymphoepithelioma

“In the second quarter of 2023, we achieved key milestones in the pivotal NAVAL-1 study of Nana-val by enabling the advancement of this global clinical trial into Stage 2 and establishing EBV-positive PTCL as Nana-val’s leading indication.

Key Points: 
  • “In the second quarter of 2023, we achieved key milestones in the pivotal NAVAL-1 study of Nana-val by enabling the advancement of this global clinical trial into Stage 2 and establishing EBV-positive PTCL as Nana-val’s leading indication.
  • Prioritization also enables the allocation of resources to those indications with the greatest probability of success and market opportunity in key geographies.
  • Patients with extranodal NK/T-cell lymphoma (ENKTL) and other ultra-rare subtypes of EBV+ lymphoma will continue to be enrolled.
  • In July 2023, Viracta received a Notice of Allowance from the US Patent and Trademark Office on Viracta’s patent claims directed to a next-generation formulation of nanatinostat.

Viracta Therapeutics Reports First Quarter 2023 Financial Results and Provides Clinical Program Updates

Retrieved on: 
Monday, May 8, 2023
Lymphoma, Research, Stage 2, Investment, Patient, SAN, Toxic leukoencephalopathy, Therapy, Stomach, Pharmaceutical industry, Leiomyosarcoma, Lymphoepithelioma

SAN DIEGO, May 08, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced financial results for the first quarter of 2023 and recent clinical program updates.

Key Points: 
  • “With progress from both of our clinical programs accelerating, we have the opportunity to achieve several important milestones this year.
  • An update on NAVAL-1’s first lymphoma subtype that may advance from Stage 1 to Stage 2 is anticipated in the second quarter of 2023.
  • Potential for additional update(s) on other NAVAL-1 lymphoma subtype(s) in the second half of 2023.
  • The Company remains on track to report complete Phase 1b dose escalation data and select a recommended Phase 2 dose (RP2D) in the second half of 2023.